Adjuvant Systemic Therapies in Breast Cancer

Leonel F. Hernandez-Aya, Ana M. Gonzalez-Angulo

Research output: Contribution to journalReview articlepeer-review

61 Scopus citations


Although some women with early breast cancer (BC) may be cured with loco-regional treatment alone, up to 20% of patients with early-stage BC will ultimately experience treatment failure and recurrence. A substantial portion of the success in improving clinical outcomes of patients with BC is related to the standardized use of adjuvant therapies. The identification of tumor subtypes with prognostic value has contributed to the idea of tailoring treatments using biologic predictive factors to identify the patients who will most likely respond to therapy and minimize the exposure of " nonresponders" to the side effects of the treatment.

Original languageEnglish
Pages (from-to)473-491
Number of pages19
JournalSurgical Clinics of North America
Issue number2
StatePublished - Apr 2013


  • Adjuvant
  • Adjuvant HER-2-targeted therapy
  • Adjuvant chemotherapy
  • Adjuvant endocrine
  • Breast cancer


Dive into the research topics of 'Adjuvant Systemic Therapies in Breast Cancer'. Together they form a unique fingerprint.

Cite this